Cell Source, Inc. financial data

Symbol
CLCS on OTC
Location
New York, NY
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2024 - 14 Nov 2024

Key Ratios

Label TTM Value / Value Unit Change %
Debt-to-equity -101% % 0.73%
Return On Equity 30% % -21%
Return On Assets -2152% % -20%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 43,468,184 shares 14%
Common Stock, Shares, Outstanding 43,253,897 shares 12%
Common Stock, Value, Issued $43,254 USD 12%
Weighted Average Number of Shares Outstanding, Basic 42,426,449 shares 11%
Weighted Average Number of Shares Outstanding, Diluted 42,426,449 shares 11%

Income Statement

Label TTM Value / Value Unit Change %
General and Administrative Expense $2,133,302 USD -21%
Operating Income (Loss) $4,172,385 USD 4.9%
Nonoperating Income (Expense) $1,058,853 USD 13%
Net Income (Loss) Attributable to Parent $5,231,238 USD 6.7%
Earnings Per Share, Basic 0 USD/shares 11%
Earnings Per Share, Diluted 0 USD/shares 11%

Balance Sheet

Label TTM Value / Value Unit Change %
Other Assets, Current $543 USD -84%
Assets $264,660 USD 6.6%
Accounts Payable, Current $2,036,128 USD 29%
Liabilities $19,205,216 USD 18%
Retained Earnings (Accumulated Deficit) $45,848,723 USD -13%
Stockholders' Equity Attributable to Parent $18,940,556 USD -18%
Liabilities and Equity $264,660 USD 6.6%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $173,852 USD 44%
Net Cash Provided by (Used in) Financing Activities $151,672 USD -31%
Common Stock, Shares Authorized 200,000,000 shares 0%
Common Stock, Shares, Issued 43,253,897 shares 12%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $22,180 USD 75%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $22,992 USD 790%
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Additional Paid in Capital $26,862,811 USD 9.4%
Share-based Payment Arrangement, Expense $288,895 USD -12%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%